Two years after the National Cancer Institute (NCI) launched its newly formed cooperative group system for clinical trial research, some researchers say adjustment to the new structure has not been easy. “I think there's a lot of frustration on the ground in regard to the whole reorganization, and a lot of skepticism as to whether it's done any good,” says Walter Stadler, MD, chief of the section of hematology/oncology at The University of Chicago Medicine in Illinois.
展开▼
